A Phase 1 Study of PIT565 in People With B-Cell Non-Hodgkin Lymphoma

Full Title

A Phase I, Open-Label, Multi-center Study of PIT565 in Patients with Relapsed and/or Refractory B-cell Malignancies

Purpose

Researchers want to find the best dose of PIT565 to use in people with non-Hodgkin lymphoma (NHL). The people in this study have B-cell NHL that keeps growing even after treatment.

PIT565 helps immune system cells find and kill cancer cells. PIT565 binds to cancer cells and to immune cells called T cells at the same time. It may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy your cancer.

If you join this study, you will get PIT565 as an injection under the skin.

Who Can Join

To join this study, there are a few conditions. You must:

• Have B-cell NHL that keeps growing or came back after treatment.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. M. Lia Palomba’s office at 646-608-3711.